BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Clifutinib Besylate readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Clifutinib Besylate\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07341672-3016@assetmemo.bio
DTSTAMP:20261121T005946Z
DTSTART;VALUE=DATE:20270423
DTEND;VALUE=DATE:20270424
SUMMARY:Clifutinib Besylate: Phase 1 readout est. (NCT07341672)
DESCRIPTION:Clifutinib Besylate\, phase 1.\nStudy: A Single-center\, Random
 ized\, Open-label\, Parallel-design Clinical Study to Evaluate the Pharmac
 okinetic Effects of Itraconazole\, Fluconazole or Efavirenz on a Single Do
 se of Clifutinib in Healthy Participants\nEstimated primary completion: 23
  April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/clifutin
 ib-besylate#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07341672
URL:https://assetmemo.bio/drug/clifutinib-besylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05586074-3016@assetmemo.bio
DTSTAMP:20261121T005946Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Clifutinib Besylate: Phase 3 readout est. (NCT05586074)
DESCRIPTION:Clifutinib Besylate\, phase 3\, Acute Myeloid Leukemia.\nStudy:
  HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML\nEstimated prima
 ry completion: 30 November 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/clifutinib-besylate#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05586074
URL:https://assetmemo.bio/drug/clifutinib-besylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05133882-3016@assetmemo.bio
DTSTAMP:20261121T005946Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Clifutinib Besylate: Phase 1/2 readout est. (NCT05133882)
DESCRIPTION:Clifutinib Besylate\, phase 1/2\, Acute Myeloid Leukemia.\nStud
 y: A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Ch
 emotherapy in the Treatment of Newly Diagnosed AML\nEstimated primary comp
 letion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/clifutinib-besylate#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05133882
URL:https://assetmemo.bio/drug/clifutinib-besylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
